The purpose of this study is to compare two different doses of enoxaparin to see which one works better at preventing major blood clots in people who have suffered severe injuries. Some patients will receive what is called an intermediate dose, which is a medium amount of the medication, while others will receive a standard dose, which is the usual amount doctors typically prescribe. Some patients will receive placebo. The study will look at whether patients develop serious blood clots such as deep vein thrombosis, which are clots that form in the deep veins of the legs, or pulmonary embolism, which are clots that travel to the lungs.

Patients in this study will receive injections under the skin of either the intermediate dose or standard dose of enoxaparin for up to 14 days while they are recovering from their injuries. During this time, doctors will carefully monitor patients for any signs of blood clots or bleeding problems. The study will also track whether patients experience any major bleeding, since blood-thinning medications can sometimes increase the risk of bleeding. All participants will be followed for 30 days after starting the treatment to see how well they recover and whether they develop any complications related to blood clots or bleeding.

The purpose of the study is to understand how these medications might reduce the risk of blood clots and improve the overall outlook for patients with pancreatic cancer. Participants will receive one of the medications or a placebo during their neoadjuvant treatment. The study will monitor the occurrence of blood clots, any bleeding complications, and the progression of the disease. Patients will be followed for at least five years or until they pass away.

Throughout the study, blood samples will be collected at various times to observe changes in blood clotting activity. These samples will be taken before starting neoadjuvant treatments, between chemotherapy cycles, after these treatments, and at several intervals during the follow-up period. This research hopes to provide valuable insights into the prevention of blood clots in pancreatic cancer patients and its potential impact on their survival and quality of life.

Participants in the study will receive a 2.5 mg dose of Apixaban, which is a film-coated tablet taken orally. The study will monitor the levels of thrombin in the blood at specific times after taking the medication. This will help researchers understand how Apixaban works in preventing blood clots in patients with multiple myeloma and those undergoing knee replacement surgery. The study will also measure the concentration of Apixaban in the blood over a 12-hour period to observe how the body processes the medication.

The trial will continue for a period of time to gather enough data to make meaningful comparisons between the two groups. By studying the effects of Apixaban in these patients, researchers hope to improve the understanding of its role in preventing blood clots, which can be a serious complication in both multiple myeloma and after knee surgery. The findings from this study may help in optimizing treatment strategies for these conditions in the future.

Participants in the study will be randomly assigned to receive either asundexian or apixaban. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will last for a period of up to 33 days, during which the safety and effectiveness of the treatments will be closely monitored.

The main goal is to see if asundexian is at least as effective as apixaban in preventing stroke and systemic embolism, and to assess the risk of major bleeding, which is a significant concern with blood-thinning medications. The study will also look at other outcomes, such as the occurrence of minor bleeding, cardiovascular events, and overall mortality. This research aims to provide valuable information on the potential benefits and risks of asundexian compared to apixaban for people with atrial fibrillation at risk of stroke.

The purpose of the study is to evaluate whether treatment with these blood thinners affects the risk of bleeding that requires medical attention or leads to death within 30 days of starting the treatment. Participants in the study will receive either TINZAPARIN or DALTEPARIN through a subcutaneous injection, which means the medication is injected under the skin. The study will monitor patients over a period of time to observe any major bleeding events or other health outcomes.

Throughout the study, researchers will track various health indicators, such as the need for blood transfusions, the occurrence of pulmonary embolism (a blockage in the lung’s blood vessels), and any signs of heparin-induced thrombocytopenia (a condition where the blood has a lower than normal number of platelets). The study will also look at overall survival rates and the length of hospital stays. This information will help determine the safety and effectiveness of these blood thinners in treating patients with venous thromboembolism.

The purpose of the study is to evaluate how well TAK-330 works compared to the standard treatment, known as 4F-PCC, in reversing the effects of Factor Xa Inhibitors in patients who need urgent surgery. The study will involve patients who have taken Factor Xa Inhibitors like rivaroxaban, apixaban, or edoxaban and require a reversal agent to manage bleeding risks during surgery. Participants will receive either TAK-330 or the standard treatment, and the effectiveness of the treatment will be assessed during and after the surgery.

The study will monitor the occurrence of effective blood clotting during and after the surgery, as well as any side effects or complications that may arise. The goal is to determine if TAK-330 can safely and effectively reverse the effects of Factor Xa Inhibitors, helping to manage bleeding risks in patients undergoing urgent surgical procedures. The trial is expected to continue until early 2027, with the aim of providing valuable information on the safety and efficacy of TAK-330 for patients in need of urgent medical interventions.

The purpose of the study is to see if adjusting the levels of ionized calcium in the blood after it passes through the filter can make the treatment just as effective as the current standard levels. The study will compare two different target ranges of ionized calcium to see if one is as good as the other. Patients will receive either the standard treatment or the adjusted treatment, and some may receive a placebo. The study will monitor how well the blood purification works and how long the filters last before they need to be changed.

Throughout the study, researchers will also keep an eye on any side effects, such as changes in calcium levels, and other possible complications like metabolic acidosis or hypocalcemia. The study aims to find the best way to use regional citrate anticoagulation to help patients in intensive care who need this type of blood purification. The trial is expected to continue until mid-2025.